Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The presentation will be available via webcast on Replimune's website, with a replay accessible for 90 days post-conference.

Founded in 2015 and based in Woburn, Massachusetts, Replimune is developing oncolytic immuno-gene therapies using its proprietary Immulytic™ platform, aiming to enhance immune responses to cancer treatments.

WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on Wednesday, February 24, 2021 at 8:40 AM ET.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
Westwicke Partners
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com

FAQ

When will Replimune's CEO present at the SVB Leerink Conference?

Philip Astley-Sparke, CEO of Replimune, will present on February 24, 2021, at 8:40 AM ET.

Where can I watch the Replimune conference presentation?

The presentation will be available via webcast on Replimune's website at www.replimune.com.

What is the Immulytic™ platform developed by Replimune?

The Immulytic™ platform is designed to enhance the immune response to cancer by maximizing systemic immune activation through selective viral replication.

What is the focus of Replimune's therapeutic development?

Replimune focuses on developing oncolytic immuno-gene therapies for cancer treatment.

How long will the Replimune conference replay be available?

The replay of the conference presentation will be available for approximately 90 days.